China and India are emerging as global superpowers in the API industry offering promising features, says RNCOS.
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, China and India are emerging as global superpowers in the API industry. The availability of cheap resources, such as infrastructure, labor, raw materials, etc accompanied by the advancing pharma expertise is one of the key factors backing this growth. Both the economies present a very bright opportunity for CRAMS as several pharma manufacturers outsource their APIs and intermediaries to these two low-end economies. While generics are a mainstay for the API industry in both the countries, India is posing a threat to India as its generic API industry has outshone that of China.
The rapidly evolving pharma market and increasing demands for drugs worldwide is primarily driving growth in the global API market. While the generic and the branded APIs represent equal share in the API merchant market, the growth of generics is expected to be incessant. The initiatives by the government to cut down on burgeoning costs have resulted in the active promotion of the generics market. Biotechnological APIs are also expected to evolve in the market. The rising patent expiries among the biopharmaceutical products in Europe and the US will increase the demand for bulk drugs. Further a latest report by RNCOS, also foresees the worldwide API market size to be likely to register a healthy CAGR of around 8% during 2012-2015.
The report spread in over 55 pages provides a proper understanding of the API market globally along with an idea about its current state. The key industry drivers have been covered in details along with the current and future market projections for the time period of 2012-2015. The major segments and sub-segments of the API industry have been covered along with the description of the API industry in the most promising geographies of India, China, Italy and Taiwan. The report also analyzes the opportunity assessment for companies in the global APIs market in terms of therapeutic segments and countries’ comparative index. An analysis of the emerging areas, competitive landscape, and regulatory stringency further provides a holistic understanding of the global API market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM424.htm
The rapidly evolving pharma market and increasing demands for drugs worldwide is primarily driving growth in the global API market. While the generic and the branded APIs represent equal share in the API merchant market, the growth of generics is expected to be incessant. The initiatives by the government to cut down on burgeoning costs have resulted in the active promotion of the generics market. Biotechnological APIs are also expected to evolve in the market. The rising patent expiries among the biopharmaceutical products in Europe and the US will increase the demand for bulk drugs. Further a latest report by RNCOS, also foresees the worldwide API market size to be likely to register a healthy CAGR of around 8% during 2012-2015.
The report spread in over 55 pages provides a proper understanding of the API market globally along with an idea about its current state. The key industry drivers have been covered in details along with the current and future market projections for the time period of 2012-2015. The major segments and sub-segments of the API industry have been covered along with the description of the API industry in the most promising geographies of India, China, Italy and Taiwan. The report also analyzes the opportunity assessment for companies in the global APIs market in terms of therapeutic segments and countries’ comparative index. An analysis of the emerging areas, competitive landscape, and regulatory stringency further provides a holistic understanding of the global API market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM424.htm
Source is found here.
No comments:
Post a Comment